Agios Pharmaceuticals | AGIO - Capitale Sociale E Riserve





Capitale Sociale E Riserve Cambiamento Data
AbbVie USD -3.27B 628M 2025-12
Agios Pharmaceuticals USD 1.11B 84M 2026-03
Alnylam Pharmaceuticals USD 789.18M 555.28M 2025-12
Amgen USD 8.66B 961M 2025-12
Arrowhead Research USD 568.42M 102.37M 2025-12
Astellas Pharma JPY 1.83T 65.92B 2026-03
AstraZeneca USD 47.33B 1.33B 2026-03
Bayer EUR 25.95B 3.75B 2025-12
Biogen USD 18.65B 394.9M 2026-03
BioMarin Pharmaceutical USD 6.09B 30.29M 2025-12
Bristol-Myers Squibb USD 18.55B 1.06B 2025-09
Daiichi Sankyo JPY 1.71T 57.86B 2025-12
Eli Lilly USD 26.54B 2.74B 2025-12
Exelixis USD 2.16B 619K 2025-12
Gilead Sciences USD 22.62B 1.16B 2025-12
GlaxoSmithKline GBP 17.42B 1.05B 2026-03
Incyte USD 5.62B 455.37M 2026-03
Ionis Pharmaceuticals USD 491.41M 2.32M 2026-03
Merck USD 51.85B 2.79B 2025-09
Moderna USD 8.65B 680M 2025-12
Nektar Therapeutics USD 89.83M 4.75M 2025-12
Novartis USD 46.13B 1.38B 2025-12
Novartis USD 46.13B 1.8B 2025-12
Pfizer USD 92.8B 4.11B 2025-09
Puma Biotechnology USD 115.27M 10.55M 2025-09
Regeneron Pharmaceuticals USD 31.42B 166.7M 2026-03
Roche Holding CHF 33.8B 758M 2025-12
Sarepta Therapeutics USD 1.14B 179.5M 2025-12
Vertex Pharmaceuticals USD 18.67B 1.35B 2025-12